九典制药
(300705)
| 流通市值：57.32亿 | | | 总市值：77.53亿 |
| 流通股本：3.70亿 | | | 总股本：5.00亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,268,037,308.7 | 1,511,949,503.84 | 696,028,386.21 | 2,930,677,498.58 |
| 营业收入 | 2,268,037,308.7 | 1,511,949,503.84 | 696,028,386.21 | 2,930,677,498.58 |
| 二、营业总成本 | 1,835,670,058.22 | 1,196,892,509.26 | 557,618,213.75 | 2,408,149,342.53 |
| 营业成本 | 578,944,690.44 | 384,340,563.5 | 183,926,631.68 | 784,397,754.77 |
| 税金及附加 | 27,396,744.15 | 18,108,326.44 | 8,468,848.36 | 33,241,429.7 |
| 销售费用 | 956,737,649.64 | 610,422,295.01 | 271,128,344.99 | 1,238,708,073.61 |
| 管理费用 | 89,902,249.25 | 54,202,211.99 | 28,564,970.59 | 92,286,390.25 |
| 研发费用 | 174,151,080.41 | 124,839,091.23 | 63,106,394.07 | 245,966,883.05 |
| 财务费用 | 8,537,644.33 | 4,980,021.09 | 2,423,024.06 | 13,548,811.15 |
| 其中:利息费用 | 10,433,335.49 | 6,482,654.98 | 3,210,529.72 | 18,633,745.21 |
| 其中:利息收入 | 1,989,892.25 | 1,467,467.13 | 734,413.7 | 5,447,937.63 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | -344,033.52 | 226,199.83 | 170,709.78 | 3,111,376.25 |
| 资产处置收益 | 48,150.68 | 0 | 0 | 0 |
| 资产减值损失(新) | -2,506,475.13 | -3,301,213.35 | -1,655,808.94 | -6,481,156.42 |
| 信用减值损失(新) | -62,752.81 | -657,376.73 | 1,339,396.23 | 3,456,649.29 |
| 其他收益 | 29,385,210.34 | 18,354,840.85 | 6,907,915.13 | 52,368,635.62 |
| 四、营业利润 | 458,887,350.04 | 329,679,445.18 | 145,172,384.66 | 574,983,660.79 |
| 加:营业外收入 | 2,072,712.84 | 277,697.58 | 100,184.4 | 1,636,520.18 |
| 减:营业外支出 | 8,280,784.56 | 4,378,336.83 | 2,138,943.89 | 4,426,323.17 |
| 五、利润总额 | 452,679,278.32 | 325,578,805.93 | 143,133,625.17 | 572,193,857.8 |
| 减:所得税费用 | 46,317,276.22 | 34,155,596.98 | 17,357,915.65 | 59,816,683.64 |
| 六、净利润 | 406,362,002.1 | 291,423,208.95 | 125,775,709.52 | 512,377,174.16 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 406,362,002.1 | 291,423,208.95 | 125,775,709.52 | 512,377,174.16 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 406,362,543.64 | 291,423,208.95 | 125,775,709.52 | 512,377,174.16 |
| 少数股东损益 | -541.54 | 0 | 0 | 0 |
| 扣除非经常损益后的净利润 | 391,016,726.94 | 282,781,130.52 | 123,664,550.75 | 474,683,296.68 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.82 | 0.59 | 0.25 | 1.05 |
| (二)稀释每股收益 | 0.79 | 0.58 | 0.25 | 1.04 |
| 八、其他综合收益 | 0 | 0 | 0 | 4,882,664.77 |
| 归属于母公司股东的其他综合收益 | 0 | 0 | 0 | 4,882,664.77 |
| 九、综合收益总额 | 406,362,002.1 | 291,423,208.95 | 125,775,709.52 | 517,259,838.93 |
| 归属于母公司股东的综合收益总额 | 406,362,543.64 | 291,423,208.95 | 125,775,709.52 | 517,259,838.93 |
| 归属于少数股东的综合收益总额 | -541.54 | 0 | - | - |
| 公告日期 | 2025-10-30 | 2025-08-23 | 2025-04-24 | 2025-04-24 |
| 审计意见(境内) | | | | 标准无保留意见 |